Payers “Need A Bigger Boat” To Take On Pricing Like Sovaldi’s – Kaiser Permanente Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Kaiser Permanente’s Levine and Memorial Sloan Kettering’s Bach discuss approaches to restraining specialty drug costs at May 29 health care conference. CMS’ Tavenner suggests transparency and collaborating with industry on “appropriate use” can help manage costs of Gilead’s Sovaldi.